Algenpantucel-L: Phase III data

Top-line data from the open-label, U.S. Phase III IMPRESS trial in 722 patients with surgically resected pancreatic cancer

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE